Fennec Pharmaceuticals

Fennec’s mission

Fennec Pharmaceuticals, Inc. is devoted to the fight against ototoxicity in pediatric cancer patients who receive cisplatin-based chemotherapy.

They proudly take their name from the fennec fox who has large ears that serve to be sensitive enough to hear prey underground as well as help dissipate the hot Sahara desert heat.

Ototoxicity due to Cisplatin

Cisplatin is a platinum-based therapy that is widely used and highly effective for testicular cancer. However, one of the side effects is ototoxicity or hearing loss. Therapies like Cisplatin damage the sensory hair cells of the inner ear that communicate to the nervous system and auditory cortex of the brain. This has a profound impact on quality of life after treatment.

TCAF has partnered with Fennec Pharmaceuticals, a biotechnology company dedicated to work in the Neuro-ototoxicity space for patients with solid tumors who are treated with cisplatin to reduce the risk of hearing loss.

Fennec HEARS™ strives to ensure that you have the support you and your family need now. Fennec HEARS™ is a single source program for both patient financial and product access support.

Fennec has developed a product named PEDMARK, which is the first and only FDA-approved sodium thiosulfate (STS) formulation for cisplatin-induced ototoxicity. No generic approved product exists or can be directly compared, which means PEDMARK cannot be not substitutable with any other STS formulation. To find more information please ask your doctor and visit www.pedmark.com.

Fennec doesn’t want the cost to stand in the way of someone receiving PEDMARK. They have developed a Patient Assistance Program that is committed to providing access to PEDMARK for eligible patients without insurance coverage. To see if you qualify for assistance, call a Fennec HEARS™ Care Coordinator at 1-833-7PEDMARK (1-833-773-3627) or fill out the enrollment form.